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The cyclic repetition of sleep and wakefulness states is essential to the basic functioning 
of all higher animals, including humans. As understanding of the neurobiology of sleep 
increases, clinicians no longer view it as a passive state (ie, sleep as merely the absence 
of wakefulness). Sleep is an active neurobehavioral state that is maintained through a 
highly organized interaction of neurons and neural circuits in the central nervous system 
(CNS). 
DEFINING SLEEP 
Sleep physicians define human sleep on the basis of an individual's observed behavior 
and accompanying physiologic changes in the brain's electrical activity as the brain 
transitions between wakefulness and sleep. Behaviorally, human sleep is characterized by 
reclined position, closed eyes, decreased movement, and decreased responsivity to 
internal and external environment. The responsiveness to stimuli is not completely 
absent; a sleeper continues to process some sensory information during sleep, and 
meaningful stimuli are more likely to produce arousals than nonmeaningful ones. A 
sound of one's own name is more likely to arouse a sleeper than some other sound, and 
the cry of her infant is more likely to arouse a sleeping mother than a cry of another 
infant. 
CONSTITUENTS OF SLEEP 
Sleep consists of two strikingly different states, rapid-eye-movement (REM) sleep and 
non-REM (NREM) sleep. NREM sleep can be subdivided further into four stages. 
Polysomnography is the “gold standard” technique that simultaneously records the three 
physiologic measures that define the main stages of sleep and wakefulness. These 
measures include muscle tone, recorded through electromyogram (EMG); eye 
movements, recorded through electro-oculogram (EOG); and brain activity, recorded 
through electroencephalogram (EEG) [1]. The clinical polysomnogram, the purpose of 
which is to detect findings that are characteristic of certain sleep disorders, includes, in 
addition to these three variables, the following: monitors for airflow at the nose and 
mouth, respiratory effort strain gauges placed around the chest and abdomen, and 
noninvasive oxygen saturation monitors that function by introducing a beam of light 
through the skin. Other parameters include the electrocardiogram and EMG of the 
anterior tibialis muscles, which are intended to detect periodic leg movements. Finally, a 
patient's gross body movements are monitored continuously by audiovisual means. 
The EEG pattern of drowsy wakefulness consists of low-voltage rhythmic alpha activity 
(8–13 cycles per second [Hz]). In stage 1 of NREM sleep, the low-voltage mixed 
frequency theta waves (4–8 Hz) replace alpha rhythm of wakefulness. Slow 
asynchronous eye movements are seen on the EOG in the beginning of stage 1 sleep and 
disappear in a few minutes. The muscle activity is highest during wakefulness and 
diminishes as sleep approaches. Individuals with behavioral characteristics of sleep and 
polysomnographic characteristics of stage 1 sleep may or may not perceive themselves as 
sleeping. Stage 1 is viewed as a “shallow” sleep, during which an individual can be easily 
aroused. With transition to stage 2, EEG patterns termed sleep spindles and K complexes 
appear on the EEG. Sleep spindles are 12- to 14-Hz synchronized EEG waveforms with 
duration of 1.5 seconds. Sleep spindle waves arise as a result of synchronization of 
groups of thalamic neurons by the GABAergic thalamic spindle pacemaker. The origin of 
K complexes is unknown. With the onset of stage 2, the arousal threshold increases, and a 
more intense stimulus is needed to arouse a sleeper. Stages 3 and 4 of NREM sleep are 
defined by synchronized high-amplitude (>75 µV) and slow (0.5–2 Hz) delta wave EEG 
pattern. Stages 3 and 4 collectively are referred as deep sleep, delta sleep, or slow-wave 
sleep. By definition, delta waves account for 20% to 50% of EEG activity during stage 3 
and greater than 50% of EEG activity during stage 4 of sleep. Slow-wave sleep is 
associated with a higher arousal threshold than “lighter” stages of NREM sleep. No eye 
movements are detected on the EOG during stages 2, 3, and 4 of NREM sleep. The EMG 
tracks continued muscle tone decline as NREM sleep “deepens” from stages 1 to 4. 
The cortical EEG pattern of REM sleep is characterized by low voltage and fast 
frequencies (alpha or 8–13 Hz). This EEG pattern is referred as activated or
desynchronized and also is seen in the state of relaxed wakefulness (with eyes closed). 
Activated refers to an active mind (dreams) and the EEG pattern characteristic of 
wakefulness. Paradoxically, individuals in REM sleep, although activated, are 
behaviorally less responsive than during the wake state [2], [3]. Desynchronized refers to 
the random-appearing wave pattern seen on the REM sleep EEG, which is contrasted 
with the synchronized uniform wave pattern seen on the NREM sleep EEG [2], [3]. To be 
scored as REM sleep, a polysomnographic tracing must contain an activated EEG pattern 
and muscle atonia (EMG) and the presence of rapid eye movements (EOG). REM sleep 
can be subdivided further into two stages: tonic and phasic. The tonic stage is continuous 
and shows muscle atonia and desynchronized EEG as two main features. Superimposed 
on the tonic stage of REM are intermittent phasic events, which include bursts of rapid 
eye movements and irregularities of respiration and heart rate. 
SLEEP ARCHITECTURE 
Sleep typically begins with a “shallow” stage 1 of NREM sleep and “deepens” to NREM 
sleep stages 2, 3, and 4, which are followed by the first brief episode of REM sleep in 
approximately 90 minutes. After the first sleep cycle, NREM and REM sleep continue to 
alternate in a predictable fashion, each NREM-REM cycle lasting approximately 90 to 
120 minutes [1]. In the course of the night, sleep cycles recur three to seven times. Stage 
1 of NREM sleep, which lasts only a few minutes, serves as a transition from 
wakefulness to sleep and later during sleep serves as a transition between REM-NREM 
sleep cycles. Typically, stage 1 constitutes 2% to 5% of total sleep time. An increase in 
the amount or percentage of stage 1 sleep may be a sign of sleep disruption. The brief 
first period of stage 1 NREM sleep is followed by “deeper” stage 2, which lasts 
approximately 10 to 20 minutes. Stage 2 sleep normally constitutes 45% to 55% of the 
total sleep time. Stage 2 sleep progresses to stages 3 (lasting a few minutes) and 4 (lasting 
40 minutes). Stage 3 constitutes 5% to 8% of the total sleep time, and stage 4 constitutes 
10% to 15% of the total sleep time. Stages 3 and 4 of NREM sleep predominate during 
the first third of the night. The first REM period is brief and occurs approximately 90 
minutes after sleep onset; subsequent REM cycles occur approximately 90 to 120 minutes 
apart. REM sleep episodes become longer as the night progresses, and the longest REM 
periods are found in the last third of the night [4], [5]. NREM sleep accounts for 75% to 
80% and REM sleep accounts for 20% to 25% of the total sleep time [1], [3], [6], [7], [8]. These 
proportions commonly vary with age (see later section on effects of age). 
PHYSIOLOGIC FUNCTIONS IN SLEEP 
AUTONOMIC NERVOUS SYSTEM DURING SLEEP  
The parasympathetic drive is higher during all stages of sleep than in relaxed 
wakefulness. The sympathetic drive increases significantly during phasic REM, decreases 
slightly during tonic REM, and remains relatively unchanged during relaxed wakefulness 
and NREM sleep. The net effect is the dominance of the parasympathetic tone during 
NREM and tonic REM sleep, and the sympathetic dominance during phasic REM [9], [10], 
[11].
BODY TEMPERATURE REGULATION  
The energy expenditure is lower during NREM sleep compared with wakefulness. The 
body temperature is maintained at a lower set-point in NREM than in wakefulness. 
During REM sleep, thermoregulatory responses of shivering and sweating are absent, and 
thermal regulation seems to cease (as in poikilothermic organisms) [9], [10], [11].
CONTROL OF RESPIRATION AND CARDIOVASCULAR FUNCTION DURING 
SLEEP  
The predominance of the parasympathetic tone and decreased energy expenditure during 
NREM sleep are responsible for decreased ventilation during this stage. The respiration 
rate in NREM sleep is regular, and cardiovascular changes are consistent with decreased 
energy expenditure. In contrast, breathing patterns and heart rate during REM sleep are 
irregular [9], [10], [11]. The irregularities in cardiovascular parameters increase the risk of 
myocardial infarctions during REM sleep in vulnerable individuals. The changes in 
ventilation, respiration, and upper airway tone make REM sleep a vulnerable period for 
individuals with obstructive sleep apnea (Table 1). 
EFFECTS OF AGE 
Age is likely the strongest factor that affects sleep continuity and the distribution of sleep 
stages through the night. The sleep pattern of newborn infants dramatically differs from 
that of adults. During the first year of life, infants sleep twice as much as adults and, in 
contrast to adults, enter sleep through REM. During the first year of life, REM sleep 
constitutes 50% of the total sleep time; the percentage occupied by REM sleep decreases 
to adult levels of 20% to 25% by age 3 years and remains at that level until old age. 
NREM-REM cycles, controlled by the ultradian process, are present at birth, but the 50- 
to 60-minute cycle periods in newborns are shorter than the approximately 90-minute 
periods in adults. Slow-wave sleep is not present at birth, but develops by age 2 to 6 
months. The amount of slow-wave sleep steadily declines from maximal levels in the 
young to almost nonexistent amounts in the elderly [1], [10], [12]. In addition to loss of slow-
wave sleep, sleep changes in the elderly include sleep fragmentation, increased 
percentage of stage 1 sleep, and decreased ability to maintain continuous sleep at night 
and wakefulness during the day. Contrary to commonly held beliefs, the need to sleep 
does not decrease with the advancing age; what changes in the elderly is the ability to 
maintain sleep (Fig. 1) [10], [12], [13].
HOW MUCH SLEEP DOES ONE NEED? 
One needs a sufficient amount of sleep to feel alert and refreshed and to avoid falling 
asleep unintentionally during the waking hours. Most young adults average 7 to 8 hours 
of sleep nightly, but there is a significant individual and night-to-night variability in these 
figures. Genetics plays a role in determining sleep length, and voluntary sleep reduction 
plays a significant role in determining how much sleep an individual actually gets. Sleep 
restriction results in daytime sleepiness, and daytime sleepiness suggests that an 
individual's sleep needs have not been met [1].
REGULATION OF SLEEP AND WAKEFULNESS 
DRIVES 
Experimental studies in humans and animals led to the development of the two-process 
model, which accounts for regulation of sleep and wake time. According to the model, 
sleep is regulated by two basic processes: a homeostatic process, which depends on the 
amount of prior sleep and wakefulness, and a circadian process, which is driven by an 
endogenous circadian pacemaker, generating nearly 24-hour cycles of behavior. An 
ultradian process within sleep is believed to control the alternation between REM-
NREM sleep every 90 to 120 minutes. It is hypothesized that the interaction of 
homeostatic and circadian processes is responsible for helping humans to maintain 
wakefulness during the day and consolidated sleep at night (Fig. 2). 
HOMEOSTATIC REGULATION OF SLEEP 
Virtually all organisms have an absolute need to sleep. Humans cannot remain awake 
voluntarily for longer than 2 to 3 days, and rodents cannot survive without sleep for 
longer than few weeks [10], [14]. The homeostatic factor represents an increase in the need 
for sleep (sleep pressure) with increasing duration of prior wakefulness. The presence of 
homeostatic factor is best shown through sleep deprivation studies. When a normal 
amount of sleep is reduced, the homeostatic drive is increased, leading to increased sleep 
pressure and sleepiness during the day and increased deep sleep at night. When normal 
sleep is preserved, the homeostatic factor represents a basic increase in sleep propensity 
during waking hours. The pull of this drive builds up during wakefulness and reaches its 
peak at sleep time. Its strength declines during sleep with the lowest point (nadir) on 
awakening in the morning. 
It also is useful to differentiate sleepiness from tiredness or fatigue. A tired or fatigued 
individual does not have a propensity to fall asleep given an opportunity to do so. A 
sleepy individual is not only anergic, but also falls asleep given the opportunity to do so. 
CIRCADIAN RHYTHMS 
Humans have an endogenous circadian pacemaker with an intrinsic period of slightly 
more than 24 hours [15]. Virtually all living organisms exhibit metabolic, physiologic, and 
behavioral circadian (ie, about 24 hours) rhythms. The most obvious circadian rhythm is 
the human sleep-wake cycle. Examples of other circadian rhythms include the release of 
cortisol, thyroid-stimulating hormone, and melatonin. Most mammalian tissues and 
organs contain mechanisms capable of expressing their function in accordance with the 
circadian rhythm. The “master biologic clock,” which regulates sleep-wake and all other 
circadian rhythms, resides in the suprachiasmatic nuclei (SCN) of the hypothalamus. 
SCN are bilaterally paired nuclei located slightly above the optic chiasm in the anterior 
hypothalamus. 
Circadian clocks normally are synchronized to environmental cues (zeitgebers) by a 
process called entrainment. The process of entrainment of SCN cells is mediated through 
glutamate stimulating the N-methyl-D-aspartate receptor [16]. Light hitting the retina 
activates the release of glutamate through the retinohypothalamic tract projecting to the 
SCN [17]. In most mammals and humans, light-dark cycle is the most potent entraining 
stimulus. The modulation of the SCN by environmental cues and 
neurotransmitters/hormones is phase dependent. When light is given to a patient at night, 
it shifts the circadian clock back, whereas light exposure in early morning shifts the clock 
forward; melatonin is effective only in shifting the circadian clock when given at dawn or 
at dusk, but not during the daytime hours; cholinergic activation of the muscarinic 
receptors affects the clock only at night [18], [19].
Circadian information from the SCN is transmitted to the rest of the body after input from 
the hypothalamus. Body organ responses (eg, sleep-wake cycle, core body temperature, 
the release of cortisol, thyroid-stimulating hormone, melatonin) to the circadian rhythm is 
controlled by the SCN and modulated by the hypothalamus. The release of melatonin 
from the pineal gland, signaled by the circadian rhythm, peaks at dawn and dusk. The 
SCN contains melatonin receptors, and the circadian clock can be reset by melatonin 
through a feedback mechanism [15], [18], [20]. In the absence of environmental cues (eg, 
under conditions of sensory deprivation), the endogenous rhythmicity of the circadian 
pacemaker persists independently of the light-dark cycle [18], [21]. The genes of the SCN 
cells, through transcription-translation, are responsible for maintaining the 24-hour clock. 
Experimental mutation of these genes in animals produces prolonged or shortened 
circadian periods, whereas in humans such mutations result in abnormal circadian 
rhythms [18].
NEUROTRANSMITTERS INVOLVED IN SLEEP AND WAKEFULNESS 
Adenosine had been identified as a possible mediator of the homeostatic sleep process. It 
is an endogenous sleep-producing substance [10], [18], [22], [23], [24]. A breakdown product of 
adenosine triphosphate (ATP), adenosine is believed to be a homeostatic sleep factor that 
mediates the transition from prolonged wakefulness to NREM sleep. Adenosine mediates 
this transition by inhibiting arousal-promoting neurons of the basal forebrain. Caffeine is 
believed to promote wakefulness by blocking adenosine receptors. ATP is an important 
energy reserve in neurons. Adenosine accumulates in certain areas of the brain when 
neurons consume energy in the form of ATP during prolonged wakefulness. In animal 
studies, adenosine levels in the brain increased during sleep deprivation and returned to 
baseline during sleep [14], [25], [26]. Other substances hypothesized to be involved in 
promoting sleep and contributing to the homeostatic factor include proinflammatory 
cytokines (interleukin-1) [18], [27] prostaglandin D2, and growth hormone–releasing 
hormone [27].
Cholinergic neurons have a dual role: Some promote sleep, and others promote 
wakefulness. The serotoninergic, noradrenergic, and histaminergic wakefulness-
promoting neurons have a discharge pattern nearly opposite that of the cholinergic sleep-
promoting neurons. The discharge rate of serotoninergic, noradrenergic, and 
histaminergic neurons is fastest during wakefulness, decreases during NREM sleep, and 
virtually stops firing during REM sleep. Additionally, newly discovered peptides called 
hypocretins (also known as orexins) are thought to regulate wakefulness by interacting 
with histaminergic, aminergic, and cholinergic systems (Fig. 3). 
ACETYLCHOLINE 
Cholinergic neurons that originate in the laterodorsal and pedunculopontine tegmental 
nuclei (LDT/PPT) of the midbrain reticular formation reach the cortex by ascending 
through the thalamus and hypothalamus. These midbrain LDT and PPT areas contain two 
interspersed subsets of cholinergic neurons. One subset is responsible for the fast-
frequency and low-voltage EEG pattern of “cortical activation,” which appears in REM 
sleep and restful wakefulness. These are called wake/REM-on neurons [28]. The second 
subset is responsible for generations of REM sleep. These latter cholinergic neurons are 
called REM-on cells. The three physiologic components of REM sleep (muscle atonia, 
rapid eye movements, EEG activation/desynchronization) are controlled by different 
nulei located in the pontine reticular formation (PRF). The REM-on cholinergic neurons 
promote REM sleep by sending excitatory input to the PRF. This causes the rapid firing 
of the PRF, which produces the three cardinal physiologic components of REM sleep. 
The PRF is shut off during NREM sleep. 
Cholinergic neurons that project from the basal forebrain to the cerebral cortex and 
limbic areas are part of the vigilance-waking system. The side effects produced by 
anticholinergic medications likely result owing to a disruption of the vigilance-wake 
producing cholinergic neurons and the wake/REM-on cholinergic neurons. 
SEROTONIN AND NOREPINEPHRINE 
Serotoninergic neurons originate in the dorsal raphe nucleus and noradrenergic neurons 
originate in the locus caeruleus. Both sets of neurons act as suppressants of REM sleep 
(REM off cells) by inhibiting REM-promoting cholinergic neurons and by sending 
inhibitory input to the PRF. Serotonin and norepinephrine neurons promote cortical 
activation during wakefulness by rapid firing [29]. The noradrenergic wake-promoting 
system also was found to have an important role in the cognitive function of learning 
during the waking state. Activity of the noradrenergic system triggers an increase in the 
expression of genes associated with memory formation and learning [18]. The 
serotoninergic system was not found to have this close link to cognitive function. 
During the NREM sleep period, at the beginning of the first sleep cycle, the 
serotoninergic and noradrenergic neurons significantly reduce their firing rate. This 
removes the inhibition from the REM-on cholinergic neurons; leading to the first REM 
sleep period approximately 90 minutes later. 
HYPOCRETIN 
Hypocretins (also called orexins) are two neuropeptides (hypocretin 1 and hypocretin 2) 
with key roles in regulation of arousal and metabolism. They bind to their corresponding 
receptors (Hcrtr1 and Hcrtr2) throughout the brain and spinal cord. These peptides are 
produced by hypothalamic neurons that surround the fornix bilaterally and in the 
dorsolateral hypothalamus. These hypothalamic regions are implicated in control of 
nutritional balance, blood pressure, and temperature regulation and endocrine secretion 
and arousal. Hypocretins likely play a role in all of these functions [30].
The hypocretin-producing neurons in the hypothalamus receive direct input from the 
SCN (the circadian rhythm clock) and project to the posterior hypothalamus 
(tuberomammillary nucleus [TMN]–histamine), basal forebrain (cholinergic vigilance-
wake area), thalamus, locus caeruleus and dorsal raphe neucleus (norepinephrine and 
serotonin REM off cells), LDT, and PRF (cholinergic REM-on cells and muscle atonia) 
[30], [31]. In accordance with circadian rhythm control of hypocretin levels (through SCN 
input), their concentration is highest during the waking period. Hypocretin levels also 
increase during a period of forced sleep deprivation. It is unclear whether this increase 
during sleep deprivation represents hypocretin opposing and attempting to override the 
sleep drive or producing a stress response to sleep deprivation. Hypocretin input to the 
brainstem REM-on cells controls the switch into REM by reducing the firing rate of the 
REM-on cells during the wake period [30].
HISTAMINE 
Antihistaminergic drugs that cross the blood-brain barrier are known to produce sedation. 
The neurotransmitter histamine plays a key role in maintenance of wakefulness. 
Histaminergic neurons originate from the TMN of the posterior hypothalamus and project 
diffusely throughout the brain. In the cortex, histamine facilitates cortical arousal. 
Histaminergic neurons fire most rapidly during cortical activation in the wake state and 
turn off during REM sleep [29], [32].
HYPOTHALAMUS 
The role of the hypothalamus as a key area of the brain involved in regulation of sleep 
and wakefulness was recognized after the pandemic of encephalitis lethargica swept the 
world in the early 1900s. Thought to be a viral infection of the brain, encephalitis 
lethargica induced severe sleep abnormalities in affected individuals. Most patients 
exhibited profound and prolonged sleepiness, whereas some had severe insomnia. 
Patients affected by sleepiness were discovered to have lesions in the posterior 
hypothalamus; patients affected by insomnia were found to have lesions in the anterior 
hypothalamus[23], [33].
Since this clinical observation more than 70 years ago, numerous human and animal 
studies have elucidated further the role of the hypothalamus in the regulation of sleep. In 
accordance with these original observations, the ventrolateral preoptic nucleus in the 
anterior hypothalamus has been established as the key sleep-inducing region and the 
TMN of the posterior hypothalamus as one of the important wakefulness-promoting 
regions of the brain. 
The anterior hypothalamus contains GABAergic cells. Activity of GABAergic cells in 
the ventrolateral preoptic nucleus region is implicated in production of NREM sleep, 
whereas the GABAergic cells in the area adjacent to the ventrolateral preoptic nucleus is 
thought to promote REM sleep by inhibiting the noradrenergic (locus caeruleus) and 
serotoninergic (dorsal raphe nucleus) REM-off nuclei of the brainstem [23]. The rapid 
firing of the anterior hypothalamus region during sleep leads to inhibition of the locus 
caeruleus and dorsal raphe nucleus in the brainstem. This in effect takes the 
“noradrenergic and serotoninergic breaks” off the hypothalamic sleep generator, 
reinforcing the sleep state [33].
The posterior hypothalamus/TMN receives histaminergic input and has hypocretin 
receptors (hctr2). Histamine and hypocretin produce activation of the TMN cells, which 
leads to sustained wakefulness [23]. At the same time, hypocretin activates the 
noradrenergic and seretoninergic cells in the brainstem, which send inhibitory signals to 
the anterior hypothalamus. This in effect takes the “GABAergic breaks” off the 
hypothalamic wakefulness generator, reinforcing the wake state. 
From the point of view of evolutionary advantage, it may be important for most animals 
to be either in the fully awake or the fully asleep state and to spend little time in the 
transition state between sleep and wakefulness. The anterior and posterior regions of the 
hypothalamus work through a system of mutual inhibition in what has been referred to as 
a flip-flop switch (similar to a light switch) [33]. The hypothalamic sleep switch is quickly 
turned “on” and “off,” with both positions being equally stable. It is hypothesized that the 
circadian, homeostatic, and ultradian drives are responsible for flipping the hypothalamic 
switch into the sleep and wake positions. The hypocretin tone, which also is influenced 
by the circadian and homeostatic drives, helps to stabilize the hypothalamic switch in the 
wake position and prevent intrusion of REM sleep into the waking state [23], [33]. When the 
hypocretin tone is reduced, as in narcolepsy, this stability of the wake state is impaired 
resulting in abnormal shifts from wake to REM states (eg, cataplexy, sleep paralysis). 
 
PHARMACEUTICALS AND RECREATIONAL DRUGS 
All drugs that cross the blood-brain barrier may affect sleep. Selective serotonin reuptake 
inhibitors, tricyclic antidepressants, serotonin norepinephrine reuptake inhibitors, and 
monoamine oxidase inhibitors suppress REM sleep; acute withdrawal from these 
antidepressants is likely to produce a rebound increase in REM sleep. Barbiturates 
increase slow-wave sleep and suppress REM. Benzodiazepines suppress slow-wave sleep 
and do not affect REM. Psychostimulants, such as amphetamine and cocaine, increase 
sleep latency, fragment sleep, and suppress REM sleep [4], [10], [12].
SLEEPING AND DREAMING 
Many theories attempt to explain the biologic function of sleep, without a clear winner. 
One such theory posits that sleep serves a restorative function for the brain and body. 
Normal sleep is subjectively associated with feeling refreshed on awakening. REM sleep 
is associated with increased CNS synthesis of proteins and is crucial for the CNS 
development of infants and young humans and animals. Growth hormone secretion is 
increased, while cortisol secretion is decreased during sleep. All these can be used to 
support the restorative theory of sleep [34]. Another theory of sleep function proposes that 
sleep has a central role in reinforcement and consolidation of memory. Sleep deprivation 
experiments have highlighted the important role of REM sleep in memory function [34].
Another theory suggests that sleep is important for thermoregulatory function. 
Experiments have shown that total sleep deprivation results in thermoregulatory 
abnormalities, NREM sleep maintains thermoregulatory function, and REM sleep is 
associated with impaired thermoregulatory responses (eg, shivering, sweating) [34].
Since the middle 1950s, when REM sleep was identified, sleep research has focused on 
understanding the physiology of dreams. Most dreams (about 80%) occur during REM 
sleep; the remainder occur during NREM sleep. REM sleep dreams are more complex, 
have more emotional valence, can be bizarre, and are easier to recall. NREM sleep 
dreams are more logical and realistic, but more difficult to recall possibly because 
awakening from NREM sleep leaves a person feeling more confused and disoriented than 
awakening from REM sleep. During REM sleep, neuronal signals originating from the 
brainstem are transmitted to the cerebral hemispheres and stimulate the cortical 
association areas to produce images that compose dreams [34].
SUMMARY 
Sleep is a vital, highly organized process regulated by complex systems of neuronal 
networks and neurotransmitters. Sleep plays an important role in the regulation of CNS 
and body physiologic functions. Sleep architecture changes with age and is easily 
susceptible to external and internal disruption. Reduction or disruption of sleep can affect 
numerous functions varying from thermoregulation to learning and memory during the 
waking state. 
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Table 1 -- Physiologic changes with stages of sleep 
Parameter NREM REM 
Heart Decreases Irregular with increases and 
decreases 
Blood pressure Unchanged and stable Irregular with increases and 
decreases 
Respiration Decreased rate Irregular rate in phasic stage 
Ventilation Decreased tidal volume; 
decreased hypoxic response 
Decreased tidal volume in 
phasic stage; decreased 
hypoxic response 
Upper airway muscle tone Decreased Further decreased 
Temperature Preserved thermoregulation Increased temperature and 
poikilothermia 
Pupils Constricted Constricted in tonic stage; 
dilated in phasic stage 
Gastrointestinal Failure of inhibition of acid 
secretion; prolonged acid 
clearance 
Failure of inhibition of acid 
secretion 
Nocturnal penile 
tumescence/clitoral 
enlargement 
Infrequent Frequent 
Data From Refs. [9], [35].
Fig. 1 Sleep and age. (Data from Williams RL, Karacan I, Hursch CJ. 
Electroencephalography (EEG) of human sleep: clinical applications. New York: Wiley 
& Sons; 1974.) 
 
Fig. 2 Two-process model of sleep regulation. (Data from Edgar DM, Dement WC, 
Fuller CA. Effect of SCN lesions on sleep in squirrel monkeys: evidence for opponent 
processes in sleep-wake regulation. J Neurosci 1993;13:1065–79.) 
 
Fig. 3 Sleep: neurochemistry. BF, basal forebrain cholinergic nuclei; CR, caudal raphe; 
LDT/PPT, laterodorsal tegmental nuclei/pedunculopontine tegmental nuclei; PRF, 
pontine reticular formation; TMN, tuberomammillary nucleus; VLPO, ventrolateral 
preoptic nucleus. (From Mignot E, Taheri S, Nishino S. Sleeping with the hypothalamus: 
emerging therapeutic targets for sleep disorders. Nat Neurosci 2002;5:1072; with 
permission.) 
